A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists

M. Yadira Hurley; Mary Noel George; Craig L. Leonardi; John L. Frater

doi:10.1186/1746-1596-3-13

A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists

M. Yadira Hurley, Mary Noel George, Craig L. Leonardi, John L. Frater

Division of Anatomic and Molecular Pathology (AMP)

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Background. Therapeutic biologic agents are uncommonly associated with lymphoma. Case presentation. We report a patient with psoriasis treated with the biologic agents efalizumab (Raptiva®) and etanercept (Enbrel®), who developed painless lymphadenopathy with peripheral lymphocytosis during treatment, simulating a non-Hodgkin lymphoma clinically and pathologically. Lymphocytosis and lymphadenopathy spontaneously remitted following cessation of etanercept therapy and have not recurred. Conclusion. Distinction between clinically benign lymphoid proliferations related to antipsoriasis therapy and malignant lymphoma avoids the unnecessary use of anti-lymphoma chemotherapy.

Original language	English
Article number	13
Journal	Diagnostic Pathology
Volume	3
Issue number	1
DOIs	https://doi.org/10.1186/1746-1596-3-13
State	Published - 2008

Access to Document

10.1186/1746-1596-3-13

Cite this

@article{42d038367c284c378303566ef31aa1d8,

title = "A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists",

abstract = "Background. Therapeutic biologic agents are uncommonly associated with lymphoma. Case presentation. We report a patient with psoriasis treated with the biologic agents efalizumab (Raptiva{\textregistered}) and etanercept (Enbrel{\textregistered}), who developed painless lymphadenopathy with peripheral lymphocytosis during treatment, simulating a non-Hodgkin lymphoma clinically and pathologically. Lymphocytosis and lymphadenopathy spontaneously remitted following cessation of etanercept therapy and have not recurred. Conclusion. Distinction between clinically benign lymphoid proliferations related to antipsoriasis therapy and malignant lymphoma avoids the unnecessary use of anti-lymphoma chemotherapy.",

author = "Hurley, {M. Yadira} and George, {Mary Noel} and Leonardi, {Craig L.} and Frater, {John L.}",

year = "2008",

doi = "10.1186/1746-1596-3-13",

language = "English",

volume = "3",

journal = "Diagnostic Pathology",

issn = "1746-1596",

number = "1",

}

TY - JOUR

T1 - A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists

AU - Hurley, M. Yadira

AU - George, Mary Noel

AU - Leonardi, Craig L.

AU - Frater, John L.

PY - 2008

Y1 - 2008

N2 - Background. Therapeutic biologic agents are uncommonly associated with lymphoma. Case presentation. We report a patient with psoriasis treated with the biologic agents efalizumab (Raptiva®) and etanercept (Enbrel®), who developed painless lymphadenopathy with peripheral lymphocytosis during treatment, simulating a non-Hodgkin lymphoma clinically and pathologically. Lymphocytosis and lymphadenopathy spontaneously remitted following cessation of etanercept therapy and have not recurred. Conclusion. Distinction between clinically benign lymphoid proliferations related to antipsoriasis therapy and malignant lymphoma avoids the unnecessary use of anti-lymphoma chemotherapy.

AB - Background. Therapeutic biologic agents are uncommonly associated with lymphoma. Case presentation. We report a patient with psoriasis treated with the biologic agents efalizumab (Raptiva®) and etanercept (Enbrel®), who developed painless lymphadenopathy with peripheral lymphocytosis during treatment, simulating a non-Hodgkin lymphoma clinically and pathologically. Lymphocytosis and lymphadenopathy spontaneously remitted following cessation of etanercept therapy and have not recurred. Conclusion. Distinction between clinically benign lymphoid proliferations related to antipsoriasis therapy and malignant lymphoma avoids the unnecessary use of anti-lymphoma chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=42149139369&partnerID=8YFLogxK

U2 - 10.1186/1746-1596-3-13

DO - 10.1186/1746-1596-3-13

M3 - Article

C2 - 18366773

AN - SCOPUS:42149139369

SN - 1746-1596

VL - 3

JO - Diagnostic Pathology

JF - Diagnostic Pathology

IS - 1

M1 - 13

ER -

A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists

Abstract

Access to Document

Other files and links

Fingerprint

Cite this